Ihor R. Lemischka

Ihor R. Lemischka, Ph.D. is an internationally recognized stem cell biologist and stem cell research advocate[1] and currently both the Lillian and Henry M. Stratton Professor of Gene and Cell Medicine and Director of the Black Family Stem Cell Institute at Mount Sinai Medical Center in New York City.[2]

His work with hematopoietic stem cells (HSC) was the first to identify their novel receptor tyrosine kinases and showed that HSC can rebuild all blood cell types in a mouse whose blood cells had been destroyed.[3][4]

He has authored over 70 book chapters and publications in peer-reviewed journals.[5]

Biography

Education and post-doctoral training

Lemischka graduated from Johns Hopkins University in 1976[6] and earned his Ph.D in biology from MIT in 1983.[7] He did his post-doctoral training at MIT's Whitehead Institute.

Academic appointments

Lemischka joined Princeton University in 1986 as Assistant Professor of Molecular Biology; he became Professor in 2002.[5] In 2007, he joined the staff at Mount Sinai Medical Center, where he is currently Professor of Gene and Cell Medicine and Director of the Black Family Stem Cell Institute.

Affiliations and awards

Lemischka is a board member of the International Society for Stem Cell Research, the Journal of Visualized Experiments (JoVE) and the New York Stem Cell Foundation.[7] His awards include a Damon Runyon-Walter Winchell Postdoctoral, a Leukemia Social Special Fellowship, an American Cyanamid Preceptorship Award and the DuPont Young Faculty Grant.[5] He is a journal reviewer for Cell, Science, Nature, Nature Genetics, Nature Immunology, Nature Biotechnology, Proceedings of the National Academy of Sciences, Public Library of Science, Development, Genes & Development, Journal of Clinical Investigation and Blood.

Patents

Lemischka holds or has patents pending for the following:[8]

Patent Number Title
7465464 Populations of cells that express flk-2 receptors
7445798 Populations of cells that express FLK-1 receptors
6960446 Method for isolating cells expressing flk-2
6677434 Soluble human flk-2 protein
6613565 Use of delta-like protein to inhibit the differentiation of stem cells
5912133 Method for isolating stem cells expressing flk-1 receptors
5747651 Antibodies against tyrosine kinase receptor flk-1
5621090 Nucleic acids encoding soluble human FLK-2 extracellular domain
5548065 Tyrosine kinase receptor human flk-2-specific antibodies
5367057 Tyrosine kinase receptor flk-2 and fragments thereof
5283354 Nucleic acids encoding hematopoietic stem cells receptors flk-1
5270458 Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
5185438 Nucleic acids encoding hencatoporetic stem cell receptor flk-2

Areas of concentration

Lemischka's interests include defining the cellular and molecular mechanisms that control cell fate decisions in embryonic stem cells. Research into mouse embryonic stem cells is currently being aggressively studied in the embryonic stem cells of humans.[9]

Publications

Partial List:

References

  1. ↑ Monya Baker (October 8, 2009). "Ihor Lemischka: stem cells meet systems biology". Nature Reports. Nature. Retrieved December 22, 2009.
  2. ↑ SciVee
  3. ↑ Cass Cliatt (June 19, 2006). "Princeton scientists explore the next frontier of stem cell research". The Princeton Weekly Bulletin. Princeton University. Retrieved December 22, 2009.
  4. ↑ "Ihor Lemischka to deliver spring Dean's Lecture". Penn State Live. Penn State University. May 14, 2009. Retrieved December 22, 2009.
  5. 1 2 3 Bioconnex.org
  6. ↑ Mount Sinai School of Medicine – Faculty profile
  7. 1 2 ZoomInfo
  8. ↑ PatentGenius.com
  9. ↑ New York State Stem Cell Science

External links

This article is issued from Wikipedia - version of the Thursday, April 28, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.